Results 51 to 60 of about 38,007 (143)

Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)

Neurology and Therapy
Introduction Following NOVA (part 1) and the approval of the subcutaneous (SC) route of administration of natalizumab by the European Medicines Agency, an extension phase of the NOVA phase IIIb study (part 2) was initiated to collect patient preference ...
Heinz Wiendl, John Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A. Cohen, Douglas L. Arnold, Helmut Butzkueven, Gary R. Cutter, Gavin Giovannoni, Joep Killestein, Rose Domingo-Horne, Marie Toukam, Aimie Nunn, Amir-Hadi Maghzi, Robert Kuhelj, Tyler Lasky   +15 more
doaj   +1 more source

Optimization of individualized faricimab dosing for patients with diabetic macular edema: Protocol for the SWAN open-label, single-arm clinical trial.

PLoS ONE
PurposeIn patients with diabetic macular edema (DME) from YOSEMITE/RHINE, dual angiopoietin-2/vascular endothelial growth factor-A (VEGF-A) inhibition with faricimab resulted in visual/anatomic improvements with extended dosing.
Takao Hirano, Toshinori Murata, Shintaro Nakao, Masahiko Shimura, Miho Nozaki, Kiyoshi Suzuma, Taiji Nagaoka, Masahiko Sugimoto, Yoshihiro Takamura, Tomoaki Murakami, Keisuke Iwasaki, Jun Tsujimura, Shigeo Yoshida   +12 more
doaj   +1 more source

Treatment Patterns and Characteristics of Patients with Hereditary Angioedema Treated with Lanadelumab: A US Retrospective Chart Review

Drugs - Real World Outcomes
Background and Objective Hereditary angioedema presents as recurrent, unpredictable, and often debilitating attacks of cutaneous/submucosal swelling.
Maureen Watt, Rose Chang, Louise Huafeng Yu, Louise Clear, Maral DerSarkissian   +4 more
doaj   +1 more source

Improved antibody breadth with an extended primary dose interval of COVID-19 vaccine is overcome by boosters

Frontiers in Immunology
IntroductionDuring rollout of mRNA-based COVID-19 vaccines, several jurisdictions extended the interval between the first and second doses to prioritize wider population access to limited vaccine supply.
Jessica I. Ahmed, Samantha J. Krosta, Mandy N. Reimer, Winnie Cheung, Christine Mesa, Carmen Lopez, Rayeil J. Chua, Farah Alsattari, Alyssia Robinson, Kathy Manguiat, Naima Jahan, Bernard Abrenica, Angela Harris, Karla Cachero, Rissa Fabia, Jonathan Walker, Myo Minn Oo, Derek Stein, Derek Stein, Hezhao Ji, Hezhao Ji, Ruey-Chyi Su, Ruey-Chyi Su, Paul J. McLaren, Paul J. McLaren, Lyle R. McKinnon, Lyle R. McKinnon, Lyle R. McKinnon, T Blake Ball, T Blake Ball, Heidi Wood, John Kim, Sandra A. Kiazyk, Sandra A. Kiazyk, Catherine M. Card, Catherine M. Card   +35 more
doaj   +1 more source

Extended-Interval Gentamicin Dosing in Achieving Therapeutic Concentrations in Malaysian Neonates

The Journal of Pediatric Pharmacology and Therapeutics, 2015
OBJECTIVE: To evaluate the usefulness of extended-interval gentamicin dosing practiced in neonatal intensive care unit (NICU) and special care nursery (SCN) of a Malaysian hospital. METHODS: Cross-sectional observational study with pharmacokinetic analysis of all patients aged ≤28 days who received gentamicin treatment in NICU/SCN ...
Yee Shan, Low, Sin Li, Tan, Angeline Sl, Wan   +2 more
openaire   +3 more sources

Population pharmacokinetics and optimized dosing of piperacillin-tazobactam in hematological patients with febrile neutropenia

Antimicrobial Agents and Chemotherapy
Hematological patients with febrile neutropenia receiving piperacillin-tazobactam may experience pharmacokinetic alterations that compromise drug exposure.
Julia Laporte-Amargos, Marta Ulldemolins, María Patricia Hernández-Mitre, Jason A. Roberts, Raul Rigo-Bonnin, Francisco Carmona-Torre, Maria Huguet, Pedro Puerta-Alcalde, Montserrat Arnan, Jose Luis del Pozo, Anna Torrent, Carolina García-Vidal, Anna Sureda, Alba Bergas, Enric Sastre-Escolà, Jordi Carratalà, Carlota Gudiol   +16 more
doaj   +1 more source

Subcutaneous injections of penicillin (SCIP): Convenient and effective treatment for Māori, Pacific Peoples and their families in preventing rheumatic heart disease.

PLOS Global Public Health
Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) remain significant health issues for Māori and Pacific communities in Aotearoa New Zealand (NZ).
Julie Cooper, Monleigh Muliaumasealii, Dhevindri Moodley, Jacqui Ulugia, Anneka Anderson, Julie Bennett   +5 more
doaj   +1 more source

Extension of Dupilumab Injection Intervals in Chronic Rhinosinusitis with Nasal Polyps: A Real-World Study

Pharmaceuticals
Background/Objectives: Dupilumab is an effective long-term treatment for chronic rhinosinusitis with nasal polyps (CRSwNP), but continuous biweekly (Q2W) treatment is associated with high costs, cumulative drug exposure, and treatment burden.
Michael Habenbacher, Ulrich Moser, Angelika Lang, Ahmed Abaira, Jakob Pock, Thomas Lampl, Alexandros Andrianakis   +6 more
doaj   +1 more source

Safety and efficacy of extended versus standard interval dosing of anti-CD20 therapy in multiple sclerosis – A meta-analysis

Multiple Sclerosis Journal - Experimental, Translational and Clinical
Background Anti-CD20 therapy is a highly effective multiple sclerosis (MS) disease-modifying therapy, but may be complicated by infections, which has led to the utilization of different extended interval dosing (EID) regimens.
Mahmoud Elkhooly, Rhea Jacob, Torge Rempe   +2 more
doaj   +1 more source

Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosis

Frontiers in Immunology
Natalizumab, a monoclonal antibody used to treat multiple sclerosis, can undergo Fab-arm exchange (FAE) with endogenous IgG4, resulting in a monovalent form with reduced avidity and presumed lower potency than the parental bivalent form.
Liza M.Y. Gelissen, Stefan P.H. van den Berg, Alyssa A. Toorop, Martijn T. Wijburg, Emma C. Tallantyre, Emma C. Tallantyre, Ninotska I.L. Derksen, Floris C. Loeff, Joep Killestein, Theo Rispens, Theo Rispens, Theo Rispens, Zoé L.E. van Kempen, the NEXT-MS study group   +13 more
doaj   +1 more source